Cargando…
Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma
SIMPLE SUMMARY: Urothelial carcinoma (UC) is a common type of bladder cancer. Patients with UC that has not improved after previous treatment or has spread to other parts of the body need new treatment options. Ibrutinib is a drug approved for the treatment of blood cancers and chronic graft-versus-...
Autores principales: | Mar, Nataliya, Zakharia, Yousef, Falcon, Alejandro, Morales-Barrera, Rafael, Mellado, Begona, Duran, Ignacio, Oh, Do-Youn, Williamson, Stephen K., Gajate, Pablo, Arkenau, Hendrik-Tobias, Jones, Robert J., Teo, Min Yuen, Turan, Tolga, McLaughlin, Robert T., Peltier, Hillary M., Chong, Elizabeth, Atluri, Harisha, Dean, James P., Castellano, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251876/ https://www.ncbi.nlm.nih.gov/pubmed/37296940 http://dx.doi.org/10.3390/cancers15112978 |
Ejemplares similares
-
PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020) -
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study
por: Oh, Do-Youn, et al.
Publicado: (2023) -
Non–Muscle Invasive Papillary Urothelial Carcinoma Metastatic to the Mandible
por: Frydenlund, Noah, et al.
Publicado: (2018) -
Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer
por: Garje, Rohan, et al.
Publicado: (2020) -
Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
por: Sotelo, M., et al.
Publicado: (2020)